Mapping the role of the microbiome in the origin of asthma and allergy, a prospective clinical study

Our ambition in this project is to substantiate the correlation between environmental exposures, the early life microbiome and later disease development focusing on asthma and allergy. The novelty in this project lies in the internationally unique longitudinal analysis of the early microbiome sampled from several compartments from pregnancy and onwards since 1 week of age in 700 children.

Background and aim
Asthma and allergy are the most common chronic diseases in children in westernized countries and their incidences have more than doubled in the last decades, now affecting about 20% of all pre-school children. Early life is a critical period for environmental exposures to imprint lasting effects on the developing immune system through complex gene-environment interactions. In recent years our microbial environment has come into attention as one mediator of such effects. The Copenhagen Prospective Studies on Asthma in Childhood (COPSAC)has in ground breaking studies been focusing strongly on the role of the human microbiome in the development of chronic disease. In this project we wish to pursue the clinical assessments and the data collection in the COPSAC2010 cohort to include children at school age to complete our ongoing characterization of the human microbiome in pregnant women and their
children over time.

The overall aim of this translational project is to explore the association between alterations in the microbiome, in different body compartments, and the development of asthma and allergy in childhood.

The perspectives of this project is that manipulation of an inadequate human microbiome in early-life may prevent chronic inflammatory diseases such as asthma and allergy. The perspectives of defining a potential beneficial microbial composition could lay the ground for the development of a testable model and of innovative preventive 'next-generation probiotic' interventions. If successful, this strategy could lead to novel prevention strategies and targeted, efficient microbiota manipulation in groups at risk of developing disease due to microbiota dysbiosis.

Startdate: 01. January 2017
End date: 31. December 2019 2020
Grant doner:
The Lundbeck Foundation